CHMP recommends Cyramza + paclitaxel for advanced Gastric (stomach) or Gastroesophageal Junction (GEJ) Adenocarcinoma - Eli Lilly
Eli Lilly and Company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Cyramza (ramucirumab), in adults, in combination with paclitaxel, for the treatment of advanced Gastric (stomach) or Gastroesophageal Junction (GEJ) Adenocarcinoma following prior chemotherapy and as a monotherapy in this setting for patients for whom treatment in combination with paclitaxel is not appropriate.
This CHMP opinion is based on results from two global, randomized, double-blind and placebo-controlled Phase III studies: RAINBOW and REGARD. RAINBOW evaluated ramucirumab in combination with paclitaxel for advanced Gastric or GEJ Adenocarcinoma after prior chemotherapy while REGARD evaluated ramucirumab as a single agent in the same setting.
Related news and insights
SpringWorks Therapeutics, Inc. announced that the FDA has approved Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors who require systemic treatment
Protagonist Therapeutics, Inc. announced two additional Phase III studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ 2113 (formerly PN 235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis
Biotronik announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress